A Dosimetric Comparison of Dose Escalation with Simultaneous Integrated Boost for Locally Advanced Non-Small-Cell Lung Cancer

Table 5

Dosimetric comparison of the 3D-CRT, IMRT, and SIB-IMRT groups to the organs at risk.

	3DCRT	IMRT	SIB-IMRT2.3	SIB-IMRT2.5	SIB-IMRT2.7
Lung
Mean lung dose (Gy)	15.5 ± 3.2	15.4 ± 2.5	15.7 ± 2.7	16.1 ± 2.7	16.6 ± 2.
V5 (%)	46.4 ± 12.9	49.2 ± 9.7	49.1 ± 10.1	49.3 ± 10.6	49.9 ± 10.
V20 (%)	29.5 ± 7.	26.9 ± 4.3	27.1 ± 4.5	27.3 ± 4.7	28.0 ± 5.1
V60 (%)	2.9 ± 2.	1.3 ± 1.6	5.6 ± 2.1	6.7 ± 2.	7.7 ± 2.
Heart
Mean dose (Gy)	15.5 ± 11.4	14.1 ± 10.1	14.3 ± 10.4	14.6 ± 10.9	14.9 ± 11.2
V5 (%)	47.2 ± 32.1	59.6 ± 33.4	50.6 ± 33.8	49.3 ± 34.2	50.0 ± 33.9
V40 (%)	14.5 ± 14.7	11.9 ± 11.0	11.9 ± 11.1	12.3 ± 11.5	12.7 ± 11.9
V60 (%)	4.7 ± 6.3	2.12 ± 2.	3.1 ± 3.5	4.1 ± 4.9	4.6 ± 5.6
Eso
Mean dose (Gy)	25.7 ± 9.9	26.6 ± 9.0	26.8 ± 9.4	26.9 ± 9.6	27.4 ± 9.8
V50 (%)	26.6 ± 18.3	27.0 ± 17.1	26.5 ± 16.4	25.9 ± 16.3	26.1 ± 16.2
Maximum	62.4 ± 3.7	64.0 ± 2.3	68.0 ± 3.	73.0 ± 5.	77.6 ± 6.
Spinal cord
Maximum	42.0 ± 4.6	40.6 ± 2.9	41.5 ± 2.6	42.2 ± 2.7	43.1 ± 2.

compared with all other groups.
compared with the 3DCRT group.
compared with the other IMRT groups.